Literature DB >> 11329468

Importance of complement source in measuring meningococcal bactericidal titers.

G F Santos1, R R Deck, J Donnelly, W Blackwelder, D M Granoff.   

Abstract

Complement-mediated bactericidal antibodies in serum confer protection against meningococcal disease. The minimum protective titer is estimated to be between 1:4 and 1:8 when measured by the Goldschneider assay performed with human complement, the assay used in the 1960s to establish the correlation between bactericidal antibodies and protection. A more recently described bactericidal assay standardized by an international consortium uses rabbit complement, which is known to augment bactericidal titers. To define a protective titer measured by the standardized assay, we compared bactericidal titers against serogroup C strains measured by this assay to titers measured by the assay described by Goldschneider et al. A titer of > or =1:128 measured by the standardized assay was needed to predict with > or =80% certainty a positive titer of > or =1:4 as measured by the Goldschneider assay. However, the majority of samples with titers of 1:4 measured by the Goldschneider assay had titers of <1:128 when measured by the standardized assay. Therefore, by the results of the standardized assay such persons would be falsely categorized as being susceptible to disease. In conclusion, high bactericidal titers measured with the standardized assay performed with rabbit complement are predictive of protection, but no threshold titer is both sensitive and specific for predicting a positive titer measured by the Goldschneider assay using human complement. Up to 10% of the U.S. adult population lacks intrinsic bactericidal activity against serogroup C strains in serum and can serve as complement donors. Therefore, use of the Goldschneider assay or an equivalent assay performed with human complement is preferred over assays that use rabbit complement.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11329468      PMCID: PMC96111          DOI: 10.1128/CDLI.8.3.616-623.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  19 in total

1.  Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey.

Authors:  E A Høiby; E Rosenqvist; L O Frøholm; G Bjune; B Feiring; H Nøkleby; E Rønnild
Journal:  NIPH Ann       Date:  1991-12

2.  Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine.

Authors:  C C Peeters; H C Rümke; L C Sundermann; E M Rouppe van der Voort; J Meulenbelt; M Schuller; A J Kuipers; P van der Ley; J T Poolman
Journal:  Vaccine       Date:  1996-07       Impact factor: 3.641

3.  Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.

Authors:  S E Maslanka; J W Tappero; B D Plikaytis; R S Brumberg; J K Dykes; L L Gheesling; K B Donaldson; A Schuchat; J Pullman; M Jones; J Bushmaker; G M Carlone
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Authors:  S E Maslanka; L L Gheesling; D E Libutti; K B Donaldson; H S Harakeh; J K Dykes; F F Arhin; S J Devi; C E Frasch; J C Huang; P Kriz-Kuzemenska; R D Lemmon; M Lorange; C C Peeters; S Quataert; J Y Tai; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

5.  Standardization and control of meningococcal vaccines, group A and group C polysaccharides.

Authors:  K H Wong; O Barrera; A Sutton; J May; D H Hochstein; J D Robbins; J B Robbins; P D Parkman; E B Seligmann
Journal:  J Biol Stand       Date:  1977

6.  IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms.

Authors:  J M Griffiss; D K Goroff
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

7.  Complement-mediated bactericidal activity of human antibodies to poly alpha 2-->8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B.

Authors:  R E Mandrell; F H Azmi; D M Granoff
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

8.  Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide.

Authors:  W D Zollinger; R E Mandrell
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

9.  A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses.

Authors:  D M Granoff; S E Maslanka; G M Carlone; B D Plikaytis; G F Santos; A Mokatrin; H V Raff
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

10.  Human immunity to the meningococcus. II. Development of natural immunity.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  38 in total

1.  Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.

Authors:  C J Gill; S Ram; J A Welsch; L Detora; A Anemona
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

2.  Combined administration of serogroup B meningococcal vaccine and conjugated serogroup C meningococcal vaccine is safe and immunogenic in college students.

Authors:  J D Holmes; D Martin; C Ramsay; E Ypma; P Oster
Journal:  Epidemiol Infect       Date:  2007-08-03       Impact factor: 2.451

3.  Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide.

Authors:  Peter C Giardina; Emma Longworth; Renee E Evans-Johnson; Michaelene L Bessette; Hong Zhang; Ray Borrow; Dace Madore; Philip Fernsten
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

4.  Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.

Authors:  Ingeborg S Aaberge; Philipp Oster; Oddveig S Helland; Anne-Cathrine Kristoffersen; Ellen Ypma; E Arne Høiby; Berit Feiring; Hanne Nøkleby
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

5.  Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine.

Authors:  Peter T Beernink; Jo Anne Welsch; Lee H Harrison; Arunas Leipus; Sheldon L Kaplan; Dan M Granoff
Journal:  J Infect Dis       Date:  2007-04-05       Impact factor: 5.226

6.  Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads.

Authors:  Dace V Madore; Bruce D Meade; Fran Rubin; Carolyn Deal; Freyja Lynn
Journal:  Vaccine       Date:  2010-05-12       Impact factor: 3.641

7.  Investigation on the effect of immune selection on resistance to bactericidal antibodies to group B meningococci in vitro.

Authors:  George F Santos; Marzia Giuliani; Laura Santini; Jeanette Adu-Bobie; Mariagrazia Pizza; Rino Rappuoli; William Wacknov; John Donnelly
Journal:  Clin Vaccine Immunol       Date:  2009-08-26

Review 8.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.

Authors:  Ray Borrow; Nick Andrews; Helen Findlow; Pauline Waight; Joanna Southern; Annette Crowley-Luke; Lorraine Stapley; Anna England; Jamie Findlow; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2009-11-11

10.  Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.